Therapeutic Approach

Archive: April, 2020

Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.

  The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. LOS ANGELES (April 28, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), is urging its stockholders to vote now on the proposed merger […]

Leave Your Comments »

Ritter Pharmaceuticals, Inc. Stockholders to Vote on Proposed Merger, Special Meeting Scheduled for May 14, 2020

Ritter Pharmaceuticals, Inc. Announces Form S-4 Registration Statement Declared Effective by SEC LOS ANGELES (April 16, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019

Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES (March 31, 2020) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, Ritter” or the “Company”), a developer of therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today reported financial results for the fourth quarter and year ended December 31, 2019. […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD